Market news

The Company had previously published laboratory results on its library of Anti-Coronavirus compounds in August 2024 (J. 2024, 67, 13681−13702) and more recently in March 2026 (J.

Sunshine Biopharma Inc. (NASDAQ:SBFM) on Wednesday announced it advanced its lead Coronavirus drug candidate into IND-enabling studies. The company had previously published laboratory results on its library of compounds in August 2024 and more recently in March 2026. Background and Compound Research The company said that the nominated drug candidate for advanced development displayed nanomolar potency against the viral protease and had broad-spectrum activity against other SARS-CoV-2 variants of

FORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its Atenolol tablets of 25mg, 50mg and 100mg for the Canadian market. Atenolol is the generic equivalent of the brand name, Tenormin®.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Global anti-hypertensive drug market projected to reach $37.24 billion by 2034 Enalapril is a widely prescribed ACE inhibitor used to treat hypertension, heart failure and left ventricular dysfunction Sunshine Biopharma expects Enalapril tablets in ...

Sunshine Biopharma Inc. (NASDAQ:SBFM) announced on Wednesday that it has secured regulatory approval to introduce its generic Enalapril tablets across the Canadian market, signaling a significant strategic step into first-line antihypertensive treatments. The newly approved medication, the generic equivalent of the well-known brand Vasotec, will be available to patients in multiple dosage strengths: 2.5mg, 5mg, 10mg, and 20mg tablets. Sunshine Biopharma currently markets 60 generic prescription

Sunshine Biopharma's Amoxicillin now shipping to Canadian pharmacies in multiple dosages and strengths Launch expands Sunshine Biopharma's growing portfolio of essential prescription medications Global Amoxicillin market projected to reach approximately ...

Pharmaceutical firm Sunshine Biopharma Inc. (NASDAQ:SBFM) on Tuesday said it received regulatory approval to introduce its 2mg generic Dienogest tablets to the Canadian market. The significant milestone marks the company’s strategic expansion into women’s healthcare, specifically targeting first-line therapy for pelvic pain associated with endometriosis. Read Also: Sunshine Biopharma Stock Rallies On Canadian Approval For Generic Amoxicillin The generic prescription drugs maker in June implement

Dienogest is first-line therapy for pelvic pain associate with endometriosis The endometriosis treatment market is projected to reach $5.2 billion by 2034 FORT LAUDERDALE, FL / ACCESS Newswire / August 4, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ...

FORT LAUDERDALE, FL / ACCESS Newswire / July 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of ...

Detailed price information for Sunshine Biopharma (SBFM-Q) from The Globe and Mail including charting and trades.

FORT LAUDERDALE, FL / ACCESS Newswire / July 20, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications today announced the publication of new research ...